TLR1/TLR2 agonist induces tumor regression by reciprocal modulation of effector and regulatory T cells

Journal of Immunology

Volumn 186, Issue 4, 2011, Pages 1963-1969

  Zhang, Yi ^a   Luo, Feifei ^a   Cai, Yuchan ^a   Liu, Nan ^a   Wang, Luman ^a   Xu, Damo ^b   Chu, Yiwei ^a  

^a FUDAN UNIVERSITY   (China)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BACTERIUM LIPOPROTEIN; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR AGONIST; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER SIZE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; EFFECTOR CELL; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; LEUKEMIA; LUNG CARCINOMA; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; WILD TYPE;

ANIMALS; ANTINEOPLASTIC AGENTS; BACTERIAL PROTEINS; CARCINOMA, LEWIS LUNG; DOWN-REGULATION; HUMANS; LEUKEMIA, EXPERIMENTAL; LIPOPROTEINS; MELANOMA, EXPERIMENTAL; MICE; MICE, KNOCKOUT; MICE, SCID; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY; TOLL-LIKE RECEPTOR 1; TOLL-LIKE RECEPTOR 2; UP-REGULATION;

EID: 79951822508     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1002320     Document Type: Article

References (50)

1. Dunn, G. P., L. J. Old, and R. D. Schreiber. 2004. The three Es of cancer immunoediting. Annu. Rev. Immunol. 22: 329-360.
2. Rosenberg, S. A., J. C. Yang, and N. P. Restifo. 2004. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10: 909-915.
3. Finn, O. J. 2008. Cancer immunology. N. Engl. J. Med. 358: 2704-2715.
4. Sakaguchi, S. 2005. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat. Immunol. 6: 345-352.
5. Zou, W. 2006. Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 6: 295-307.
6. Vignali, D. A., L. W. Collison, and C. J. Workman. 2008. How regulatory T cells work. Nat. Rev. Immunol. 8: 523-532.
7. Colombo, M. P., and S. Piconese. 2007. Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat. Rev. Cancer 7: 880-887.
8. Curiel, T. J., G. Coukos, L. Zou, X. Alvarez, P. Cheng, P. Mottram, M. Evdemon-Hogan, J. R. Conejo-Garcia, L. Zhang, M. Burow, et al. 2004. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10: 942-949.
9. Ghiringhelli, F., P. E. Puig, S. Roux, A. Parcellier, E. Schmitt, E. Solary, G. Kroemer, F. Martin, B. Chauffert, and L. Zitvogel. 2005. Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+ CD25+ regulatory T cell proliferation. J. Exp. Med. 202: 919-929.
10. Takeda, K., T. Kaisho, and S. Akira. 2003. Toll-like receptors. Annu. Rev. Immunol. 21: 335-376.
11. Liew, F. Y., D. Xu, E. K. Brint, and L. A. O'Neill. 2005. Negative regulation of toll-like receptor-mediated immune responses. Nat. Rev. Immunol. 5: 446-458.
12. Yang, Y., C. T. Huang, X. Huang, and D. M. Pardoll. 2004. Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat. Immunol. 5: 508-515.
13. Kanzler, H., F. J. Barrat, E. M. Hessel, and R. L. Coffman. 2007. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat. Med. 13: 552-559.
14. Conroy, H., N. A. Marshall, and K. H. Mills. 2008. TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours. Oncogene 27: 168-180.
15. Cherfils-Vicini, J., S. Platonova, M. Gillard, L. Laurans, P. Validire, R. Caliandro, P. Magdeleinat, F. Mami-Chouaib, M. C. Dieu-Nosjean, W. H. Fridman, et al. 2010. Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance. J. Clin. Invest. 120: 1285-1297.
16. Conforti, R., Y. Ma, Y. Morel, C. Paturel, M. Terme, S. Viaud, B. Ryffel, M. Ferrantini, R. Uppaluri, R. Schreiber, et al. 2010. Opposing effects of toll-like receptor (TLR3) signaling in tumors can be therapeutically uncoupled to optimize the anticancer efficacy of TLR3 ligands. Cancer Res. 70: 490-500.
17. Komai-Koma, M., L. Jones, G. S. Ogg, D. Xu, and F. Y. Liew. 2004. TLR2 is expressed on activated T cells as a costimulatory receptor. Proc. Natl. Acad. Sci. USA 101: 3029-3034.
18. Gelman, A. E., J. Zhang, Y. Choi, and L. A. Turka. 2004. Toll-like receptor ligands directly promote activated CD4+ T cell survival. J. Immunol. 172: 6065-6073.
19. Caron, G., D. Duluc, I. Frémaux, P. Jeannin, C. David, H. Gascan, and Y. Delneste. 2005. Direct stimulation of human T cells via TLR5 and TLR7/8: flagellin and R-848 up-regulate proliferation and IFN-gamma production by memory CD4+ T cells. J. Immunol. 175: 1551-1557. (Pubitemid 41023056)
20. Cottalorda, A., C. Verschelde, A. Marçais, M. Tomkowiak, P. Musette, S. Uematsu, S. Akira, J. Marvel, and N. Bonnefoy-Berard. 2006. TLR2 engagement on CD8 T cells lowers the threshold for optimal antigen-induced T cell activation. Eur. J. Immunol. 36: 1684-1693.
21. Caramalho, I., T. Lopes-Carvalho, D. Ostler, S. Zelenay, M. Haury, and J. Demengeot. 2003. Regulatory T cells selectively express toll-like receptors and are activated by lipopolysaccharide. J. Exp. Med. 197: 403-411.
22. Crellin, N. K., R. V. Garcia, O. Hadisfar, S. E. Allan, T. S. Steiner, and M. K. Levings. 2005. Human CD4+ T cells express TLR5 and its ligand flagellin enhances the suppressive capacity and expression of FOXP3 in CD4+CD25+ T regulatory cells. J. Immunol. 175: 8051-8059.
23. Peng, G., Z. Guo, Y. Kiniwa, K. S. Voo, W. Peng, T. Fu, D. Y. Wang, Y. Li, H. Y.Wang, and R. F.Wang. 2005. Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. Science 309: 1380-1384. (Pubitemid 41209366)
24. Takeuchi, O., S. Sato, T. Horiuchi, K. Hoshino, K. Takeda, Z. Dong, R. L. Modlin, and S. Akira. 2002. Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins. J. Immunol. 169: 10-14. (Pubitemid 34686113)
25. Liu, H., M. Komai-Koma, D. Xu, and F. Y. Liew. 2006. Toll-like receptor 2 signaling modulates the functions of CD4+ CD25+ regulatory T cells. Proc. Natl. Acad. Sci. USA 103: 7048-7053.
26. Sutmuller, R. P., M. H. den Brok, M. Kramer, E. J. Bennink, L. W. Toonen, B. J. Kullberg, L. A. Joosten, S. Akira, M. G. Netea, and G. J. Adema. 2006. Toll-like receptor 2 controls expansion and function of regulatory T cells. J. Clin. Invest. 116: 485-494.
27. Ingale, S., M. A. Wolfert, J. Gaekwad, T. Buskas, and G. J. Boons. 2007. Robust immune responses elicited by a fully synthetic three-component vaccine. Nat. Chem. Biol. 3: 663-667.
28. Garay, R. P., P. Viens, J. Bauer, G. Normier, M. Bardou, J. F. Jeannin, and C. Chiavaroli. 2007. Cancer relapse under chemotherapy: why TLR2/4 receptor agonists can help. Eur. J. Pharmacol. 563: 1-17.
29. Brandau, S., and H. Suttmann. 2007. Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: a success story with room for improvement. Biomed. Pharmacother. 61: 299-305.
30. Murata, M. 2008. Activation of Toll-like receptor 2 by a novel preparation of cell wall skeleton from Mycobacterium bovis BCG Tokyo (SMP-105) sufficiently enhances immune responses against tumors. Cancer Sci. 99: 1435-1440. (Pubitemid 351761735)
31. Curtin, J. F., N. Y. Liu, M. Candolfi, W. D. Xiong, H. Assi, K. Yagiz, M. R. Edwards, K. S. Michelsen, K. M. Kroeger, C. Y. Liu, et al. 2009. HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med. 6: e10.
32. Schneider, C., T. Schmidt, C. Ziske, K. Tiemann, K. M. Lee, V. Uhlinsky, P. Behrens, T. Sauerbruch, I. G. H. Schmidt-Wolf, P. F. Mühlradt, et al. 2004. Tumour suppression induced by the macrophage activating lipopeptide MALP-2 in an ultrasound guided pancreatic carcinoma mouse model. Gut 53: 355-361. (Pubitemid 38241329)
33. Grauer, O. M., J. W. Molling, E. Bennink, L. W. J. Toonen, R. P. M. Sutmuller, S. Nierkens, and G. J. Adema. 2008. TLR ligands in the local treatment of established intracerebral murine gliomas. J. Immunol. 181: 6720-6729.
34. Asprodites, N., L. Zheng, D. Geng, C. Velasco-Gonzalez, L. Sanchez-Perez, and E. Davila. 2008. Engagement of Toll-like receptor-2 on cytotoxic T-lymphocytes occurs in vivo and augments antitumor activity. FASEB J. 22: 3628-3637.
35. Kim, S., H. Takahashi, W. W. Lin, P. Descargues, S. Grivennikov, Y. Kim, J. L. Luo, and M. Karin. 2009. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 457: 102-106.
36. Huang, B., J. Zhao, S. Shen, H. Li, K. L. He, G. X. Shen, L. Mayer, J. Unkeless, D. Li, Y. Yuan, et al. 2007. Listeria monocytogenes promotes tumor growth via tumor cell toll-like receptor 2 signaling. Cancer Res. 67: 4346-4352. (Pubitemid 46815083)
37. Ferlay, J., P. Autier, M. Boniol, M. Heanue, M. Colombet, and P. Boyle. 2007. Estimates of the cancer incidence and mortality in Europe in 2006. Ann. Oncol. 18: 581-592. (Pubitemid 46359643)
38. Mandelboim, O., E. Vadai, M. Fridkin, A. Katz-Hillel, M. Feldman, G. Berke, and L. Eisenbach. 1995. Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides. Nat. Med. 1: 1179-1183.
39. Barber, D. L., E. J. Wherry, and R. Ahmed. 2003. Cutting edge: rapid in vivo killing by memory CD8 T cells. J. Immunol. 171: 27-31.
40. Salaun, B., I. Coste, M. C. Rissoan, S. J. Lebecque, and T. Renno. 2006. TLR3 can directly trigger apoptosis in human cancer cells. J. Immunol. 176: 4894-4901.
41. Rayburn, E. R., W. Wang, R. W. Zhang, and H. Wang. 2007. Experimental therapy for colon cancer: anti-cancer effects of TLR9 agonism, combination with other therapeutic modalities, and dependence upon p53. Int. J. Oncol. 30: 1511-1519.
42. Parkinson, T. 2008. The future of toll-like receptor therapeutics. Curr. Opin. Mol. Ther. 10: 21-31.
43. Schmidt, C. 2007. Clinical setbacks for toll-like receptor 9 agonists in cancer. Nat. Biotechnol. 25: 825-826.
44. Seif, A. E., D. M. Barrett, M. Milone, V. I. Brown, S. A. Grupp, and G. S. Reid. 2009. Long-term protection from syngeneic acute lymphoblastic leukemia by CpG ODN-mediated stimulation of innate and adaptive immune responses. Blood 114: 2459-2466.
45. Sato, E., S. H. Olson, J. Ahn, B. Bundy, H. Nishikawa, F. Qian, A. A. Jungbluth, D. Frosina, S. Gnjatic, C. Ambrosone, et al. 2005. Intraepithelial CD8+ tumorin-filtrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl. Acad. Sci. USA 102: 18538-18543.
46. Alvaro, T., M. Lejeune, M. T. Salvadó, C. Lopez, J. Jaén, R. Bosch, and L. E. Pons. 2006. Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. J. Clin. Oncol. 24: 5350-5357.
47. Galon, J., A. Costes, F. Sanchez-Cabo, A. Kirilovsky, B. Mlecnik, C. Lagorce-Pagès, M. Tosolini, M. Camus, A. Berger, P.Wind, et al. 2006. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313: 1960-1964. (Pubitemid 44498003)
48. Gao, Q., S. J. Qiu, J. Fan, J. Zhou, X. Y. Wang, Y. S. Xiao, Y. Xu, Y. W. Li, and Z. Y. Tang. 2007. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J. Clin. Oncol. 25: 2586-2593.
49. Boraska Jelavić, T., M. Barisić, I. Drmic Hofman, V. Boraska, E. Vrdoljak, M. Peruzović, I. Hozo, Z. Puljiz, and J. Terzić. 2006. Microsatelite GT polymorphism in the toll-like receptor 2 is associated with colorectal cancer. Clin. Genet. 70: 156-160.
50. Sun, J., F. Wiklund, S. L. Zheng, B. Chang, K. Bälter, L. Li, J. E. Johansson, G. Li, H. O. Adami, W. Liu, et al. 2005. Sequence variants in Toll-like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk. J. Natl. Cancer Inst. 97: 525-532.